Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7100-0.0500 (-1.81%)
At close: 4:00PM EDT
2.7200 +0.01 (+0.37%)
After hours: 05:25PM EDT
Advertisement

Moleculin Biotech, Inc.

5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
713 300 5160
http://www.moleculin.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. Walter V. KlempFounder, Chairman, Pres & CEO778.14kN/A1960
Mr. Jonathan P. Foster CPAExec. VP & CFO568.61kN/A1964
Dr. Donald H. PickerChief Scientific Officer438.16kN/A1946
Dr. Waldemar Priebe Ph.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Robert C. Shepard FACP, M.D., F.A.C.P.Chief Medical Officer of AnnamycinN/AN/A1952
Dr. Sandra L. SilbermanChief Medical Officer of New ProductsN/AN/A1956
Ms. Jacqueline NorthcutConsultantN/AN/A1962
Mr. Louis Ploth Jr.Independent AdvisorN/AN/A1954
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Corporate Governance

Moleculin Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement